A systematic review of 26 studies found that glucocorticoids combat migraine through multiple molecular mechanisms, including reducing the neuropeptide CGRP, inhibiting nitric oxide, and suppressing NF-κB-driven neuroinflammation.
26 studies, 20-year spanThis systematic review synthesized two decades of research to identify how glucocorticoids target CGRP, NF-κB, nitric oxide, and other molecular pathways involved in migraine pathogenesis.
What the researchers found
The systematic review of 26 articles (2004-2024) identified multiple molecular mechanisms by which glucocorticoids alleviate migraine:
- Reduced calcitonin gene-related peptide (CGRP) levels — CGRP is a neuropeptide central to migraine pathophysiology
- Decreased matrix metalloproteinase-9 (MMP-9) expression — MMP-9 degrades blood-brain barrier integrity
- Inhibited nitric oxide synthesis — nitric oxide drives vasodilation and sensitization
- Modulated transcription factors NF-κB and AP-1 — master regulators of inflammatory gene expression
- Reduced pro-inflammatory cytokines IL-1β and TNF-α
- Limited prostaglandin synthesis via COX-2 inhibition
These pathways collectively suppress both central and peripheral sensitization in the trigeminovascular system.
Why it matters
Migraine affects over a billion people worldwide, and while new CGRP-targeted therapies have transformed treatment, glucocorticoids remain important for acute severe attacks and treatment-resistant cases. Understanding that glucocorticoids work partly by reducing CGRP — the same neuropeptide targeted by the newest migraine drugs — helps explain their effectiveness and may guide more strategic use. This review suggests glucocorticoids have underappreciated value specifically in migraines with strong neuroinflammatory features.
How the study worked
The authors conducted a systematic review of literature published between 2004 and 2024, selecting 26 articles that examined the molecular mechanisms of glucocorticoid action in migraine. The analysis focused on neuroinflammatory mediators, blood-brain barrier integrity, and nociceptive signaling pathways. Studies were evaluated for their contributions to understanding how glucocorticoids affect specific molecular targets relevant to migraine pathogenesis.
What this study cannot tell us
As a systematic review, the quality and conclusions depend on the underlying studies, which likely varied in design and rigor. The review covers mechanisms identified in laboratory and clinical studies but does not perform a meta-analysis of clinical outcomes. The Cureus publication venue, while peer-reviewed, has different editorial standards than top-tier journals. The specific contexts in which glucocorticoids are most beneficial for migraine (dose, timing, patient subtype) remain incompletely defined.
How to read the evidence
This is a systematic review — a higher level of evidence than individual studies — synthesizing 26 articles over 20 years. However, it does not include a meta-analysis of clinical outcomes, and the quality of individual included studies varies, placing it at a moderate-high evidence level for mechanistic understanding.
When this study was published
Published in 2025, this is a very current review synthesizing research from 2004 to 2024. The findings are highly relevant given the ongoing evolution of CGRP-targeted migraine therapies and the search for multi-mechanism treatment approaches.
The bigger picture
CGRP has become the central therapeutic target in modern migraine treatment, with monoclonal antibodies (like erenumab and fremanezumab) and small molecule antagonists (gepants) revolutionizing prevention and acute care. This review reveals that glucocorticoids — older, less targeted drugs — actually modulate the same neuropeptide pathway along with multiple other inflammatory cascades. This positions glucocorticoids as a multi-target approach that may complement newer CGRP-specific therapies, particularly in patients with refractory or neuroinflammation-driven migraine.
Questions still open
- Could combining glucocorticoids with CGRP-targeted therapies provide synergistic migraine relief through complementary mechanisms?
- Which migraine patient subtypes — based on neuroinflammatory biomarkers — would benefit most from glucocorticoid treatment?
- Do the CGRP-reducing effects of glucocorticoids persist long enough to provide meaningful prophylactic benefit?
Common questions
How do glucocorticoids reduce migraine pain at the molecular level?
Are glucocorticoids better than the newer CGRP medications for migraine?
Read the original research
Molecular Mechanisms of Glucocorticoid Action in Migraine: A Systematic Review of Neuroinflammatory and Vascular Pathways.
Cureus, 17(11), e96074
Citation
da Silva Lopes, Luciano; Krymchantowski, Abouch; Jevoux, Carla; Krymchantowski, Ana Gabriela; Maria Coelho de Moura, Camila M; Soares, Adriana A; de Sá, Marco Antônio Pereira; Val, Sabrina Nayara de Araújo; Dos Santos, Renato Mendes; Silva-Néto, Raimundo Pereira. (2025). Molecular Mechanisms of Glucocorticoid Action in Migraine: A Systematic Review of Neuroinflammatory and Vascular Pathways.. Cureus, 17(11), e96074. https://doi.org/10.7759/cureus.96074